Published in Neuroendocrinology on February 20, 2007
Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc (2010) 1.33
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg (2011) 1.21
Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc (2011) 1.15
Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 0.83
Hypergastrinemia. Gastroenterol Rep (Oxf) (2015) 0.82
Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol (2016) 0.75
Clinical features of gastroenteropancreatic tumours. Prz Gastroenterol (2015) 0.75
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. Gastrointest Endosc (2011) 2.82
Metastatic carcinoid tumors: a clinical review. Oncologist (2005) 2.80
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Deep Vein Thrombosis of the Upper Extremity. Dtsch Arztebl Int (2017) 2.68
Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res (2008) 2.66
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology (2003) 2.43
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 2.38
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol (2006) 2.34
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care (2008) 2.22
Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA (2004) 2.20
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 2.16
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology (2012) 2.12
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology (2012) 1.99
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging (2014) 1.92
Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum (2002) 1.91
The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch (2006) 1.82
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med (2005) 1.78
Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology (2013) 1.77
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol (2006) 1.74
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 1.70
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68
Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med (2006) 1.68
Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology (2007) 1.67
Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol (2009) 1.67
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Assessment of gene-by-sex interaction effect on bone mineral density. J Bone Miner Res (2012) 1.58
Is idiopathic chronic pancreatitis an autoimmune disease? Clin Gastroenterol Hepatol (2005) 1.57
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med (2008) 1.55
Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology (2004) 1.54
GISTogram: a graphic presentation of the growing GIST complexity. Virchows Arch (2013) 1.51
Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem (2003) 1.50
Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment. Radiology (2005) 1.48
Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg (2010) 1.48
Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol (2002) 1.47
Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. J Rheumatol (2005) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res (2010) 1.45
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records. Aging Clin Exp Res (2010) 1.44
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med (2006) 1.44
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch (2010) 1.42
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology (2009) 1.42
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology (2005) 1.39
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
The role of estrogens in melanoma and skin cancer. Carcinogenesis (2009) 1.38
EUS-guided fine-needle tissue acquisition by using a 19-gauge needle in a selected patient population: a prospective study. Gastrointest Endosc (2011) 1.33
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol (2007) 1.33
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 1.33
Benefit of a clipping device in use in intestinal bleeding and intestinal leakage. Gastrointest Endosc (2011) 1.32
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging (2002) 1.31
Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res (2002) 1.29
Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol (2008) 1.29
Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol (2009) 1.29
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology (2009) 1.28
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine (2012) 1.28
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med (2010) 1.27
Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology (2007) 1.26
A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab (2004) 1.25
Multiple endocrine neoplasia type 2. Orphanet J Rare Dis (2006) 1.23
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging (2009) 1.23
Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol (2011) 1.22